Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?

Porwit, Anna LU (2015) In Current Hematologic Malignancy Reports 10(3). p.309-317
Abstract

This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.

Please use this url to cite or link to this publication:
author
publishing date
type
Contribution to journal
publication status
published
subject
keywords
Diagnosis, Dysplasia, Flow cytometry, Myelodysplastic syndromes, Prognosis, Response to treatment
in
Current Hematologic Malignancy Reports
volume
10
issue
3
pages
9 pages
publisher
Springer
external identifiers
  • pmid:26122389
  • scopus:84941738249
ISSN
1558-8211
DOI
10.1007/s11899-015-0272-3
language
English
LU publication?
no
id
5f1c7ddc-d553-4cd9-a3da-302490a5e48d
date added to LUP
2019-05-22 09:43:37
date last changed
2024-01-01 06:37:04
@article{5f1c7ddc-d553-4cd9-a3da-302490a5e48d,
  abstract     = {{<p>This review focuses on the most recent literature concerning flow cytometry (FCM) application for diagnosis of myelodysplastic syndrome (MDS). Aberrant FCM results have been defined as abnormalities in at least three tested features comprising at least two bone marrow (BM) cell compartments. FCM results should be interpreted together with the BM smear cytology, the morphological assessment of BM biopsy, and cytogenetic results. Including FCM in the pre-treatment assessment may provide not only diagnostic but also prognostic information. Further studies are needed to evaluate the role of FCM in individual risk assessment for MDS patients and in therapy choice and/or follow-up.</p>}},
  author       = {{Porwit, Anna}},
  issn         = {{1558-8211}},
  keywords     = {{Diagnosis; Dysplasia; Flow cytometry; Myelodysplastic syndromes; Prognosis; Response to treatment}},
  language     = {{eng}},
  month        = {{09}},
  number       = {{3}},
  pages        = {{309--317}},
  publisher    = {{Springer}},
  series       = {{Current Hematologic Malignancy Reports}},
  title        = {{Is There a Role for Flow Cytometry in the Evaluation of Patients With Myelodysplastic Syndromes?}},
  url          = {{http://dx.doi.org/10.1007/s11899-015-0272-3}},
  doi          = {{10.1007/s11899-015-0272-3}},
  volume       = {{10}},
  year         = {{2015}},
}